AstraZeneca no longer plans to seek approval of its new respiratory biologic Fasenra in chronic obstructive pulmonary disease (COPD) after the second of two Phase 3 …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
